Drug Profile
Sumatriptan - GlaxoSmithKline
Alternative Names: Imigran Nasal Spray; Imitrex Nasal SprayLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
- Mechanism of Action 5-HT1 serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Migraine
- No development reported Menstrual migraine
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 22 Feb 2016 First Generic equivalent complex product Imitrex® nasal spray approved in USA for Migrane
- 04 Oct 2013 Launched for Migraine in Argentina, Canada, Indonesia and Israel before 4 October 2013 under the trade name Imitrex® (Intranasal)